Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss – a retrospective study

M. Cioni, A. Nocera, A. Tagliamacco, S. Basso, A. Innocente, I. Fontana, A. Magnasco, A. Trivelli, C. Klersy, A. Gurrado, M. Ramondetta, S. Boghen, L. Catenacci, E. Verrina, G. Garibotto, G.M. Ghiggeri, M. Cardillo, F. Ginevri, P. Comoli

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)38-48
Number of pages11
JournalTransplant International
Volume32
Issue number1
DOIs
Publication statusPublished - 2019

Keywords

  • anti-humoral therapy
  • antibody-mediated rejection
  • complement-binding DSA
  • de novo donor-specific anti-HLA antibodies
  • pediatric kidney transplantation
  • complement component C1q
  • complement component C3d
  • HLA antibody
  • immunoglobulin
  • rituximab
  • tacrolimus
  • alloantibody
  • antibody
  • HLA antigen
  • antibody mediated rejection
  • Article
  • child
  • clinical article
  • clinical outcome
  • controlled study
  • disease association
  • drug megadose
  • drug resistance
  • estimated glomerular filtration rate
  • female
  • fluorescence analysis
  • follow up
  • graft failure
  • graft recipient
  • human
  • human cell
  • human tissue
  • kidney function
  • kidney graft rejection
  • kidney transplantation
  • low drug dose
  • male
  • plasmapheresis
  • prediction
  • priority journal
  • prognosis
  • protein binding
  • retrospective study
  • risk assessment
  • treatment failure
  • treatment outcome
  • adolescent
  • biopsy
  • donor
  • graft rejection
  • graft survival
  • immunology
  • kidney
  • multivariate analysis
  • risk
  • Adolescent
  • Antibodies
  • Biopsy
  • Child
  • Female
  • Follow-Up Studies
  • Graft Rejection
  • Graft Survival
  • HLA Antigens
  • Humans
  • Isoantibodies
  • Kidney
  • Kidney Transplantation
  • Male
  • Multivariate Analysis
  • Prognosis
  • Retrospective Studies
  • Risk
  • Rituximab
  • Tissue Donors

Cite this